5 results
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed CLL.Secondary objectives are to evaluate clinical benefit,…
Primary: To determine whether ofatumumab 3, 30 or 60 milligrams (mg) given subcutaneously (SQ), reduces the cumulative number of new T1 GdE brain lesions over a period of 12 weeks, as compared with placebo.Secondary: Cumulative number of new T1 GdE…
Our primary objective is to provide a model which accounts for the inconsistencies in the pharmacological literature regarding the role of the noradrenergic and cholinergic system in visuo-spatial attention. Recently we started a University Medical…
This study (AMYPAD Diagnostic and Patient Management Study) will determine in a real-life clinical setting for whom diagnostic amyloid PET imaging is appropriate, when this is best performed, and how the resulting information is influencing…
The aim of this study is to evaluate the additional value of quantitative amyloid imaging analysis for modelling and assessing Alzheimer*s Disease (AD) dementia risk in individuals without dementia, compared to a range of existing cognitive, imaging…